Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund

Executive Summary

NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.

Advertisement

Related Content

NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited
PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent
IQWiG: Tafinlar/Mekinist Benefit 'Considerable' In Men With Melanoma, But Still Better In Women
Pfizer's Xalkori Approved In EU As First-Line NSCLC Treatment
EU's CHMP positive on Novartis's ceritinib

Topics

Advertisement
UsernamePublicRestriction

Register

SC065483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel